ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

The papers that matter: 10 August to 16 August 2026

The 10 most important of the 78 papers published that week and summarised on Y, ranked by what verified readers said would change practice, then by strength of design and size. Secondary analyses come last.
Oncology · Breast Cancer Res Treat · 2026-08-13

Meta-analysis of 4 phase III trials (17,748 participants) of adjuvant CDK4/6 inhibitors in HR+/HER2− early breast cancer: iDFS benefit was similar in pre-/peri-menopausal (HR 0.80) and postmenopausal (HR 0.79) patients; no significant subgroup difference for iDFS or OS.

Meta-analysisn = 17,748
Bender et al. The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials

Previous weekNext weekAll weeks

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.